Trump Lets Big Corporations Dodge $40 Billion in Taxes as He Jacks Up Costs for Working Class

President Trump’s withdrawal from a global corporate tax initiative is reported to have helped major U.S. companies avoid at least $40 billion in income taxes. The New York Times cited examples including Thermo Fisher Scientific cutting taxes by $3.5 billion via Malta and Honeywell reducing its tax bill by $301 million, while at least 88 large U.S. corporations reportedly paid no federal income tax in fiscal 2025. The article points to broader pro-corporate tax policy and OECD agreement changes that could support after-tax earnings for multinationals, but the impact is primarily policy-driven rather than an immediate market catalyst.

Analysis

This is less about a one-time tax headline and more about a durable margin regime change for a subset of large-cap multinationals with high non-U.S. profit mobility. The immediate winners are companies with already centralized IP, treasury, or licensing structures and enough foreign earned income to exploit blending mechanics; the losers are firms with large U.S. tax cash outflows and limited restructuring flexibility. Second-order, this widens the gap between companies that can engineer effective tax rates downward and domestic-demand names that cannot, which should keep index-level earnings optics stronger than underlying top-line breadth.

The more interesting market effect is not just higher after-tax EPS, but a reduction in the penalty for aggressive global footprint optimization. That tends to favor software, payments, life sciences tools, and industrials with meaningful cross-border intangible income, while pressuring competitors that are more U.S.-incidence-heavy or politically exposed. It also raises the probability of “silent” capital allocation shifts: more buybacks, less domestic reinvestment, and more scrutiny from procurement-sensitive customers if public pressure builds around firms benefiting from federal contracts.

Catalyst risk is political, but the timing is asymmetric. In the next 1-3 quarters, this is mostly a support for reported EPS and buyback capacity; over 12-24 months, the risk is either OECD countermeasures, congressional revision of the offshore tax rules, or targeted contract/regulatory backlash against names seen as too dependent on federal spending. The market is likely underpricing the fact that some of these savings can be clawed back if the policy becomes salient in an election cycle, which argues for owning beneficiaries tactically but avoiding complacency on duration.

Key Decisions for Investors

• Long AXP / short domestic U.S. financials with limited foreign profit flexibility for 1-3 months; favor the leg with the most mobile international earnings, targeting 5-8% relative outperformance if offshore tax efficiency stays in focus.
• Long PYPL vs. payment processors with more U.S.-centric economics on a 1-2 quarter horizon; the setup is for incremental after-tax EPS support and buyback capacity, with downside limited unless policy rhetoric turns into legislation.
• Long TMO, short a basket of U.S.-centric medtech/tools peers for 3-6 months; if tax efficiency is rewarded, TMO should keep a valuation premium, but treat this as a relative-value trade rather than a directional long.
• Reduce or hedge HON into strength with a 6-12 month horizon; defense-linked exposure creates headline risk if public scrutiny shifts from tax planning to contractor optics, making the risk/reward less attractive than the pure EPS uplift suggests.
• Use PEP as a lower-beta beneficiary but prefer call spreads over outright longs for 2-4 months; the tax tailwind is real, but consumer staples should not re-rate much unless investors start paying for after-tax resilience across the group.